Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) is recorded as a service provider in 38 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 38 trials · Latest update first
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Efficacy and Tolerability of Fixed Duration Teclistamab and Talquetamab for Frail Patients with Newly Diagnosed Multiple Myeloma (2 Cohort Study) - the EMN 37 FITFIX FOR FRAIL Trial
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants with Late-Onset Pompe Disease
Sponsor Denali Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
HOVON 173 AML: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multi-cohort Study Applying Innovative MRD Techniques for Transplant Eligible Participants with Previously Untreated Multiple Myeloma - TAURUS
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy - EMN17/54767414MMY3014
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
HOVON 156 AML: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II
Sponsor Rare Thyroid Therapeutics International AB
- Start (EU)
- Latest update
- Estimated end
A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
Sponsor Universitaetsklinikum Ulm AöR
- Start (EU)
- Latest update
- Estimated end
Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimer’s Disease Dementia
Sponsor Exciva GmbH
- Start (EU)
- Latest update
- Estimated end
A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)
Sponsor Norges Teknisk-Naturvitenskapelige Universitet NTNU
- Start (EU)
- Not reported
- Latest update
- Estimated end
HOVON 139 CLL: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of Gazyvaro (obinutuzumab) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens. (GIVE trial).
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 172 MF: A phase 1b/2 trial with tasquinimod in patients with myelofibrosis (primary, post-PV or post-ET) refractory to or intolerant for JAK2 inhibition: the TasqForce trial
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)?
The 2026-10-09 snapshot links Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) to 38 distinct CTIS trials. Recorded services include Laboratory services, Medical expertise, Medical writing, Clinical monitoring, among 22 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)?
The most frequently recorded therapeutic areas are Haematological Malignancies, Genetic and Congenital Disorders, Neurology, Endocrinology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) conducted?
The linked trials record locations in 20 countries, including Netherlands, Germany, Italy, Norway, Belgium. These are trial locations, not confirmed office locations or countries where Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) delivered services.
What can this page tell me about Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)'s trial experience?
Browse 38 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC). Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)